EP3727350A1 - Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations - Google Patents
Dispositif pour le maintien de l'homeostasie metallique, et ses utilisationsInfo
- Publication number
- EP3727350A1 EP3727350A1 EP18842805.6A EP18842805A EP3727350A1 EP 3727350 A1 EP3727350 A1 EP 3727350A1 EP 18842805 A EP18842805 A EP 18842805A EP 3727350 A1 EP3727350 A1 EP 3727350A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticles
- metal
- maintaining
- chelating agent
- homeostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to the field of medical devices, more particularly devices for extracting within an organism metals.
- the use of these devices makes it possible, for example, to prevent and / or treat pathologies related to a deregulation of metal homeostasis in the body, for example neurological diseases.
- Chelation therapy which aims to decrease the concentration of metal ions has been used for many years in cases of acute poisoning by metals.
- a number of chelants are already accepted in humans, each of which is associated with a particular metal group (Crisponi et al., Coordination Chemistry Reviews, 2015).
- Chelation therapy has also been shown to be an indispensable tool for the treatment of transfused patients with b-Thalassemia. In fact, patients who have been transfused many times suffer from the accumulation of iron in the body.
- iron deposits are regulated by the intravenous or oral administration of iron chelating agents such as desferrioxamine, deferiprone or deferasirox (P.V. Bemhardt et al., Dalton Trans, 2007).
- D-penicillamine and trientine (orally) chelation therapy is also currently used to extract copper cations and treat Wilson's disease, resulting from a genetic abnormality affecting a copper transporter: ATP7B.
- This anomaly results in copper overload with increased copper circulating in the blood and leading to deposits in the organs, mainly the liver and the brain (M. L. Schilsky, Clin, Liver Dis, 2017).
- Chelation therapy has good efficacy in pre-symptomatic but reduced treatment in liver and neurological disorders (Wiggelinkhuizen et al., Aliment Pharmacol., 2009), probably because of difficulty in achieving targeted area and low specificity.
- iron In the brain, iron is predominantly localized in the substantia nigra pars compacta and in the basal ganglia with levels comparable to those of the liver. With age, iron tends to accumulate in certain areas of the brain where it is found to be predominantly associated with ferritin and neuromelanin.
- the areas where iron levels are most likely to increase are subtsantia nigra, putamen, globus pallidus, caudate nucleus or cortex, each of these areas being associated with different neurodegenerative disorders (DJ Hare et al. Nat Rev.
- Alzheimer's disease is also characterized by disruptions in the amounts of metals in the brain but associated with other brain regions and other proteins. It seems that in this case an increase in iron levels and a decrease in copper levels are observed (SF Graham et al., J. Alzheimers Dis., 2014). Huntington's disease is another neurodegenerative disorder that results in movement disorders, cognitive decline, and psychiatric problems. In this pathology, many markers of oxidative stress are observed in the brain that can be related to a deregulation of iron homeostasis (SJA van den Bogaard et al., International Review of Neurobiology, 2013).
- deferiprone used for the treatment of transfusion-associated iron deposits for b-thalassemia
- deferipronPD NCT01539837
- the treatment lasted 6 months and was well tolerated by patients.
- a decrease in iron level was observed in the dentate nucleus and the caudate nucleus.
- Reduction of iron level in substantia nigra was observed in only 3 patients.
- iron chelators such as desferrioxamine, clioquinol, MAO, Vk-28, M30 or M30A (N. Wang et al., Biomacromolecules, 2017) have thus attracted the attention of researchers in preclinical or even clinical trials for chelation treatment of neurodegenerative diseases. Nevertheless, the effectiveness of these molecules and other iron chelating agents is still limited by their short life time in the body, their possible high dose cytotoxicity, their difficulty in crossing the blood-brain barrier and then targeting the area. the most affected brain and their prior saturation with endogenous cations.
- This study shows the potential of a targeted chelation therapy for a particular group of patients - patients with diabetes - to avoid a future accident because dio vascular.
- the inventors of the present invention have thus developed a medical device comprising at least one chelating agent for extracting metal cations.
- the invention thus relates to a device for maintaining metal homeostasis for therapeutic purposes, characterized in that it comprises means for extracting metal cations.
- the "maintenance of metal homeostasis for therapeutic purposes” means the regulation of the content of certain metals in an organism, in particular for the purpose of extracting excess metal cations which may be responsible for pathological conditions. .
- metal homeostasis refers to the homeostasis of metal cations (more particularly to the homeostasis of specific metal cations).
- said means for extracting metal cations is chosen from:
- an infusion fluid containing at least one chelating agent.
- the term "chelating agent” refers to an organic group capable of complexing at least one metal cation.
- the chelating agent is capable of complexing the metal cations that it is desired to extract, and the complexing constant log (Ko) of said chelating agent for at least one of said metal cations is greater than 10, in particular 11, 12, 13, 14, 15 and is preferably greater than or equal to 15.
- the complex chelating agent at least one of the metal cations Copper (Cu), Iron (Fe), Zinc (Zn), Mercury (Hg) ), Cadmium (Cd), Lead (Pb), Aluminum (Al), Manganese (Mn), Arsenic (As), Mercury (Hg), Cobalt (Co), Nickel (Ni), Vanadium (V), Tungsten (W) ), Zirconium (Zr), Titanium (Ti), Chromium (Cr), Silver (Ag), Bismuth (Bi), Tin (Sn), Selenium (Se), Thallium (Th), Calcium (Ca), Magnesium (Mg) ), Scandium (Sc), Ytrium (Y), Lanthan (La), Cerium (Ce), Praseodym (Pr), Neodymium (Nd), Promethium (Pm), Samarium (Sm), Europium (Eu), Gadolinium (Gd) ), Terbium (Tb), Dysprosium (Cu),
- the complex chelating agent at least one of the cations of metals Copper, Iron, Zinc, Mercury, Cadmium, Lead, Aluminum, Manganese, Magnesium, Calcium, and Gadolinium, in particular Manganese and Gadolinium. Even more advantageously, the complex chelating agent at least one of the cations of copper, iron and / or zinc metals.
- the term "at least one chelating agent" refers to the presence of a single type of chelating agent, a mixture of different chelating agents or a mixture of several identical chelating agents.
- the specificity of the chelating agent for said metals (metal cations) to be extracted is high compared to other cationic trace elements, in particular the difference between the complexation constants is preferably greater than 3, and more particularly the difference between the complexation constants with calcium and magnesium is preferably greater than 3, and even greater than 5.
- said device also contains trace elements, chosen from calcium, magnesium, iron, copper, zinc and manganese, either directly within said polymer, implant or solid, or within the perfusion fluid. This allows for example to regulate the homeostasis of essential metals.
- said means of said device makes it possible to extract the metal cations from a biological fluid, an organ or a tissue, especially when the content of said metal cations is less than 1 ppm, in particular 0 , 1 ppm, 0.01 ppm and is preferably less than 1 ppb.
- at least more than half of the cations present can be extracted.
- biological fluid refers to all the fluids with which the device of the invention can be brought into contact, such as blood, cerebrospinal fluid, synovial fluid, or liquid. peritoneal.
- organ refers to all organs with which the device of the invention can be brought into contact or within which said device can be implanted or inserted, such as the brain, the liver, pancreas, intestines or lungs.
- tissue refers to all tissues with which the device of the invention can be brought into contact or within which said device can be implanted or inserted, such as the peritoneum or the tumor tissue (if any tumor).
- said device may be contacted, inserted or implanted by endoscopy, in particular within a tumor.
- said means for extracting metal cations for example a material, and can extract a quantity of metal cations representing at least 1% of its mass, and preferably more than 10% of its mass.
- the means for extracting metals is a dialysis system
- the means for extracting metal cations is a dialysis system comprising:
- a reservoir comprising an infusion fluid.
- dialysis system refers to any system allowing the passage of metal cations through an artificial membrane.
- said device is advantageously a microdialysis device.
- microdialysis For several years, new technologies for local sampling of analytes or samples or local drug delivery (microdialysis) have developed. Microdialysis was developed in the late 1950s to recover and deliver different substances in an area of interest (CM Kho, Mol Neurobiol., 2016). Microdialysis makes it possible to collect or deliver only the samples capable of passing through a semipermeable membrane whose cutoff threshold is chosen according to the intended application. In the case of dialysis, it is often a dynamic phenomenon of diffusion, guided by the difference in concentration of diffusing species between each side of the membrane.
- the microdialysis device makes it possible to circumvent the problems of conventional chelants and to locally extract a very high proportion of the targeted metal ions, thanks to the maintenance inside a dialysis membrane of the complexing chemical species of at least one target metal.
- the complexing species are present in macromolecules or nanoparticles which have a mass greater than the cutoff threshold of the membrane so that the complexing species remain within the liquid (ie the perfusion fluid) included in the dialysis membrane.
- the dialysis device containing the complexing species is then placed at the level of the zone of interest, for example at the level of the brain in the case of the treatment of neurodegenerative diseases.
- the cations being smaller than the cutoff threshold of the membrane will be able to diffuse through the membrane to the solution comprising the chelants.
- the strong complexation properties of the ligands used will allow the chelation of the target metals even if they are present in very small quantities. This chelation will therefore reduce the concentration of free target ions in the solution inside the membrane to maintain a strong concentration gradient in the target metal ion between the concentration outside and inside the membrane to extend the extraction and maintain a flow of cations.
- an equivalent concentration of these ions may be placed in the dialysis membrane.
- any microdialysis device known to those skilled in the art may be used according to the present invention, provided that it contains a porous dialysis membrane and a reservoir comprising an infusion fluid containing at least one chelating agent as mentioned hereinabove. above.
- the cutoff threshold of the porous membrane is less than the mass of the chelating agent.
- the devices that can be used in the context of the present invention are the medical devices developed by the company M Dialysis AB, Sweden, such as microdialysis catheters (references 8010509, P000049, 8010337, this list does not include being not exhaustive ).
- the perfusion fluid is a colloidal suspension of nanoparticles whose average diameter is greater than the pores of said porous dialysis membrane, said nanoparticles comprising as active ingredient at least one chelating agent.
- the cutoff threshold of the porous dialysis membrane is less than the mass of the chelating agent, that is to say the mass of the nanoparticle comprising at least one chelating agent.
- the perfusion fluid is a colloidal suspension of polymers whose average diameter is greater than the pores of said dialysis membrane, said polymers being grafted to an active ingredient which is at least one chelating agent.
- the cutoff threshold of the porous dialysis membrane is less than the mass of the chelating agent, that is to say the mass of the polymer on which is grafted at least one chelating agent.
- the term "colloidal suspension” refers to a mixture of liquid and insoluble solid particles, which remain dispersed regularly, the particles being often sufficiently small (microscopic or nanoscopic) for the mixture to remain stable and homogeneous.
- said average diameter is greater than the pores of said dialysis membrane by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. %.
- the term "mean diameter” refers to the harmonic mean of the diameters of the nanoparticles or polymers on which at least one chelating agent is grafted.
- the size distribution of nanoparticles or polymers is for example measured using a commercial particle size analyzer, such as a Malvem Zeta Sizer Nano-S granulometer based on the PCS (Photon Correlation Spectroscopy) which is characterized by a diameter medium hydrodynamics. A method of measuring this parameter is also described in ISO 13321: l996.
- the colloidal suspension contains more than 1% by mass of nanoparticles or polymers, especially plus 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, and preferably more than 10% by mass.
- nanoparticles that can be used in a device, in particular a dialysis system or an implant, according to the present invention
- said nanoparticle comprises as active ingredient at least one chelating agent capable of complexing the metal cations, said chelating agent having a complexation constant log (K Ci ) for at least one of said metal cations is greater than 10, and preferably greater than or equal to 15.
- sica-based nanoparticles means nanoparticles characterized by a silica mass percentage of at least 8%.
- polysiloxane-based nanoparticles refers to nanoparticles characterized by a silicon mass percentage of at least 8%.
- polysiloxane means an inorganic crosslinked polymer consisting of a chain of siloxanes.
- R is an organic molecule bonded to silicon by a covalent bond Si-C n is an integer between 1 and 4.
- polysiloxane especially includes the polymers resulting from condensation by the tetraethylorthosilicate (TEOS) sol gel method and aminopropyltriethoxysilane (APTES).
- TEOS tetraethylorthosilicate
- APTES aminopropyltriethoxysilane
- said nanoparticle thus comprises: at. polysiloxanes, with a silicon mass ratio of at least 8% of the total mass of the nanoparticle, preferably between 8% and 50% of the total mass of the nanoparticle,
- chelating agents preferably in a proportion of between 5 and 1000, and preferably between 5 and 100 per nanoparticle
- metal elements for example in a proportion of between 5 and 100, and preferably between 5 and 20, by nanoparticle, said metal elements being complexed with chelating agents.
- said nanoparticle is of formula (I) below:
- N is between 20 and 50000, preferably between 50 and 1000.
- O is between 0 and 2 n
- Chi, Ch 2 and Ch 3 are chelating agents, identical or different, connected to the Si polysiloxanes by a covalent Si-C bond; a, b and c are integers between 0 and n and a + b + c is less than or equal to n, preferably a + b + c is between 5 and 100, for example between 5 and 20,
- Gf are targeting grafts, identical or different from each other, each linked to Si by an Si-C bond and resulting from the grafting of a targeting molecule allowing the targeting of the nanoparticles to biological tissues of interest, for example to tumor tissue, f is an integer between 0 and n.
- the nanoparticles that can be used according to the present invention do not comprise metallic elements.
- said nanoparticle comprises only elements a. (polysiloxanes or silica) and b. (chelating agents).
- the chelating agents complex the metal cations Cu, Fe, Zn, Hg, Cd, Pb, Mn, Al, Ca, Mg, Gd.
- the chelating agents are obtained by grafting (covalent bond) on the nanoparticle of one of the following complexing molecules or its derivatives, such as polycarboxylic acids, polyamines and derivatives thereof, chosen from: DOTA (acid l, 4,7, lO-tetraazacyclododecane-N, N, N ", N '" - tetraacetic acid), DTPA (diethylene triamine penta acetic acid ), D03A-pyridine of formula (I) below:
- EDTA (2,2 ', 2 ", 2"' - (ethane-1,2-diyldinitrilo) tetraacetic acid), EGTA (ethylene glycol-bis (2-aminoctylthio) -N, N, N ', N' - tetraacetic), BAPTA (1,2-bis (o-aminophenoxy) ethano-N, N, N ', N' -tetraacetic acid), NOTE (1,4,7-triazacyclononane-1,4,7-triacetic acid) , DOTAGA (2- (4,7,10-tris (carboxymethyl) -1,4,7,10,10-tetraazacyclododecanyl) pentanedioic acid), DFO (deferoxamine), amide derivatives such as DOT AM (1, 4,7,10-tetrakis (carbamoylmethyl) -1,4,7,10,10 tetraazacyclo
- said above chelating agents are linked directly or indirectly by covalent bonding to the polysiloxane silicias of the nanoparticle.
- directly binding refers to the presence of a molecular "linker” or “spacer” between the nanoparticle and the chelating agent, said linker or spacer being covalently bound to one of the constituents of the nanoparticle.
- said nanoparticle is a polysiloxane-based nanoparticle with a mean diameter of between 3 and 50 nm, comprising the chelating agent obtained by grafting DOTA, DOTAGA or DTPA onto the nanoparticle.
- said nanoparticle is a polysiloxane-based nanoparticle of an average size greater than 20 kDa and less than 1 MDa, comprising the chelating agent obtained by grafting DOTA, DOTAGA or DTPA onto the nanoparticle.
- said colloidal suspension comprising said nanoparticles also contains trace elements, chosen from calcium, magnesium, iron, copper, zinc or manganese.
- nanoparticles according to the present invention can be obtained according to the process described in the patent application FR1053389.
- polymers may be used in place of the aforementioned nanoparticles.
- said polymers are grafted to at least one chelating agent.
- the term "polymer” refers to any macromolecule formed by the covalent linking of a very large number of repeating units which are derived from one or more monomers.
- the polymers preferably used in the present invention are for example of the family of chitosan, polyacrylamides, polyamines or polycarboxylic.
- they may be polymers containing amino functions such as chitosan.
- said polymer is biocompatible.
- the chelating agents or their derivatives grafted onto said polymers are polycarboxylic polyamino acids and their derivatives, especially chosen from: DOTA, DTP A, OD3A-pyridine of formula (I) above, EDTA, EGTA, BAPTA, NOTE, DOTAGA, DFO, DOTAM, NOTAM, DOTP, NOTP, TETA, TETAM and TETP or mixtures thereof.
- said above chelating agents are linked directly or indirectly by covalent bonding to the polymer or to a polymer chain of more than 10 kDa and preferably more than 100 kDa.
- the term "indirect” bond means the presence of a molecular "linker” or “spacer” between the polymer and the chelating agent, said linker or spacer being covalently bound to one of the constituents of said polymer. .
- the chelating agents or their derivatives grafted onto said polymers will comprise dithiocarbamate functions.
- said polymer grafted with a chelating agent is chosen from: chitosan grafted with DPTA-BA or chitosan grafted with DFO.
- said colloidal suspension comprising said polymers also contains trace elements, chosen from calcium, magnesium, iron, copper, zinc or manganese.
- Chelating molecules that can be used in a device according to the present invention
- the perfusion fluid is a solution of chelating molecules.
- Said chelating molecules may have a greater average diameter than the pores of said dialysis membrane, that is to say greater than the cutoff threshold of the membrane in order to be maintained within the liquid of the dialysis membrane, or they may have an average diameter less than the pores of said porous dialysis membrane, and in this case they may pass through the pores of the membrane before passing into the body and be naturally eliminated by the kidneys or liver.
- said chelating molecules have a complexation constant log (K Ci ) for at least one of said metal cations greater than 10, and preferably greater than or equal to 15.
- said solution of chelating molecules also contains trace elements, chosen from calcium, magnesium, iron, copper, zinc or manganese.
- the means for extracting metal cations is an implant comprising at least one chelating agent.
- the means for extracting metal cations is an implant on which is grafted at least one chelating agent.
- an “implant” is any element intended to be introduced into an organism. They may be “polymers” or “any other solid” as described in this specification.
- the polymers are as mentioned above, usable within an infusion fluid.
- any other solid includes, without being restrictive, ceramic, metal, composite, solid or porous parts, optionally functionalized on the surface or non-functionalized on the surface, and which may have different shapes (such as only balls, tubes, plates, ).
- said implant can be implanted, in particular temporarily and then extracted.
- said implant may be implanted within the brain, liver, pancreas, ... of the subject to be prevented and / or treated.
- Said implant can be resorbable and naturally be gradually eliminated by the body.
- Said implant may also comprise at least one chelating agent which diffuses slowly in the body, for example a diffusion less than 100 mg in chelating molecules released per day, and preferably less than 10 mg / day and / or allowing a diffusion of less than 1 % of the total mass per day.
- Said implant can be put in direct contact with the tissues or under the skin.
- said implant may be in a reservoir with a dialysis fluid in contact with the subject to be treated.
- the present invention relates to the use of a colloidal suspension as mentioned above, particularly usable in a device such as those mentioned above.
- the invention thus relates to a colloidal suspension of nanoparticles comprising an active principle, for its use for therapeutic purposes, characterized in that it is contained in a device for maintaining metallic homeostasis comprising a porous dialysis membrane, and in that the average diameter of said nanoparticles is greater than the pores of the porous dialysis membrane of said device
- said device is a microdialysis device.
- the invention also relates to a colloidal suspension of polymers grafted to an active ingredient, for its use for therapeutic purposes, characterized in that it is contained in a device for maintaining the metal homeostasis comprising a porous dialysis membrane, and in that the average diameter is greater than the pores of said porous dialysis membrane, said polymers being grafted to an active ingredient.
- said device is a microdialysis device.
- the invention relates to a device for maintaining metal homeostasis according to any one of claims 1 to 13, characterized in that said device comprises means enabling it to be brought into contact, through a membrane. of dialysis, or its implantation within:
- a biological fluid such as blood, cerebrospinal fluid, synovial fluid or peritoneal fluid, or
- an organ such as the brain, liver, pancreas, intestines or lungs, or a tissue, such as the peritoneum or tumor tissue.
- the invention relates to a colloidal suspension mentioned above for its use in the maintenance of metal homeostasis.
- the invention relates to a colloidal suspension mentioned above for its use in the treatment of neurological diseases or cerebral degenerations, such as Parkinson's disease, Alzheimer's disease, NBIA (Neurodegeneration with Brain Accumulation, also known as neurodegeneration with iron overload), Wilson's disease, or Huntington's disease.
- neurological diseases or cerebral degenerations such as Parkinson's disease, Alzheimer's disease, NBIA (Neurodegeneration with Brain Accumulation, also known as neurodegeneration with iron overload), Wilson's disease, or Huntington's disease.
- the invention relates to a colloidal suspension mentioned above for its use in the treatment of autism.
- the invention relates to a colloidal suspension mentioned above for use in the treatment of type II diabetes or cardiovascular diseases.
- the invention relates to a colloidal suspension mentioned above for its use in the treatment of tumors.
- the present invention relates to the use of a nanoparticle as mentioned above, especially usable in a device such as those mentioned above.
- the invention thus relates to a polysiloxane-based nanoparticle having a diameter greater than 3 nm, preferably less than 50 nm, for its therapeutic use in a device for maintaining metallic homeostasis.
- said nanoparticle comprising as active principle at least one chelating agent capable of complexing metal cations, and characterized in that its complexation constant log (Ko) for at least one of said metal cations is greater than 10, and preferably greater or equal to 15.
- said device is a microdialysis device.
- the invention relates to a nanoparticle mentioned above for its use in maintaining metal homeostasis.
- the invention relates to a nanoparticle mentioned above for its use in the treatment of neurological diseases or cerebral degenerations, such as NBA-like diseases, Parkinson's disease, Alzheimer's disease, Wilson's disease or Huntington's disease.
- neurological diseases or cerebral degenerations such as NBA-like diseases, Parkinson's disease, Alzheimer's disease, Wilson's disease or Huntington's disease.
- the invention relates to a nanoparticle mentioned above for its use in the treatment of autism. According to another preferred embodiment, the invention relates to a nanoparticle mentioned above for its use in the treatment of type II diabetes or caro-vascular diseases.
- the invention relates to a nanoparticle mentioned above for its use in the treatment of tumors.
- the present invention relates to the use of a polymer as mentioned above, in particular usable in a device such as those mentioned above.
- the invention thus relates to a polymer, for its use for therapeutic purposes in a device for maintaining metal homeostasis, said polymer being grafted to at least one chelating agent capable of complexing metal cations, and characterized in that its complexation constant log (Ko) for at least one of said metal cations is greater than 10, and preferably greater than or equal to 15.
- said device is a microdialysis device.
- the invention relates to a polymer mentioned above for its use in the maintenance of metal and / or protein homeostasis.
- the invention relates to a polymer mentioned above for its use in the treatment of neurological diseases or cerebral degenerations, such as NBA-like diseases, Parkinson's disease, Alzheimer's disease, Wilson's disease or Huntington's disease.
- neurological diseases or cerebral degenerations such as NBA-like diseases, Parkinson's disease, Alzheimer's disease, Wilson's disease or Huntington's disease.
- the invention relates to a polymer mentioned above for its use in the treatment of autism.
- the invention relates to a polymer mentioned above for its use in the treatment of type II diabetes or caro-vascular diseases.
- the invention relates to a polymer mentioned above for its use in the treatment of tumors.
- the present invention also relates to a method for extracting metal cations in a subject comprising administering an implant on which at least one chelating agent is grafted, or the use of an infusion fluid containing at least one chelating agent within a device such as those mentioned above.
- said "subject” refers to a man or an animal to be prevented or treated.
- Figure 1 shows the image obtained at the end of the infusion of the MnCl 2 solution. It is a coronal section at the level of the microdialysis membrane (black dot). The highlight surrounding the membrane is the presence of Mn 2+ (MRI positive contrast agent).
- Figure 2 shows the image obtained at the end of the infusion with the suspension of nanoparticles. It is a coronal section at the level of the microdialysis membrane (black dot). The highlight surrounding the membrane is the presence of Mn 2+ (MRI positive contrast agent).
- FIG. 3 represents the image corresponding to the difference of the two preceding images (represented in FIGS. 1 & 2) and highlighting the decrease in tissue concentration in Mn 2+ (highlighting at the level of the microdialysis probe).
- Figure 4 shows the image obtained at the end of the infusion with the MnCl 2 solution. It is a coronal section at the level of the microdialysis membrane (black dot). The highlight surrounding the membrane is the presence of Mn 2+ (MRI positive contrast agent).
- Figure 5 shows the image obtained at the end of the infusion with saline. It is a coronal section at the level of the microdialysis membrane (black dot). The highlight surrounding the membrane is the presence of Mn 2+ (MRI positive contrast agent).
- FIG. 6 represents the image corresponding to the difference of the two preceding images (represented in FIGS. 4 and 5) and highlighting the absence of a drop in tissue concentration in Mn 2+ (quasi-absence of highlighting at the level of the probe of microdialysis).
- Figure 7 shows the MRI image of solutions 1, 2, 3, 4 and 5.
- the animal is placed under gaseous anesthesia (2.5% isoflurane under 0 2 / N 2 (80:20)) using a heating mat used during the procedure and the phase wake up.
- gaseous anesthesia 2.5% isoflurane under 0 2 / N 2 (80:20)
- a heating mat used during the procedure and the phase wake up.
- lidocaine Xylovet 21.33 mg / ml
- lidocaine 4 mg / kg diluted in 0.9% NaCl with a volume injected of 10 m ⁇ / g.
- the cranial box is disengaged in order to position a micro-drill (diameter ⁇ 1 mm) for the drilling of the cranial box.
- the probe is placed under stereotaxis.
- the dialysis cannula (diameter ⁇ 500 ⁇ m) is gently introduced into the brain at the desired position and depth.
- a quick setting fixing resin is applied and screwed onto the skull of the animal.
- the skin is then sewn to close the wound.
- an analgesic (Buffycare) is administered subcutaneously.
- the administration of the analgesic is repeated at intervals of 8 to 12 hours for 2 days following the installation of the microdialysis probe.
- a subcutaneous injection of 0.9% NaCl (of the order of 0.5 ml for the mouse, 5 ml for the rat) is carried out at the beginning of the procedure.
- an ophthalmic ointment (Liposic) is applied at the beginning of the procedure.
- the spectroscopy and MRI imaging protocol is performed on D3.
- the protocol is performed on animals under gas anesthesia (2.5% isoflurane under 0 2 / N 2 (80:20)) using a heating mat used during the procedure and the waking phase and with breath control during NMR acquisitions.
- the microdialysis probe Prior to positioning the animal in MRI (Bruker Biospin 4.7 Tesla), the microdialysis probe (2 mm long membrane, 6 kDa cutoff, CMA Microdialysis AB, Kista, Sweden) is inserted into the cannula. microdialysis.
- An IRM surface antenna Doty scientif ⁇ c, 8 mm in diameter, used in transmission and reception, is positioned on the skull of the animal at the vertical of the microdialysis probe.
- MRI acquisitions Tl-weighted Flash sequence, 2 ms echo time, 150 ms repetition time, coronal slices, 1 mm slice thickness, 3 minute acquisition time) are performed continuously during the infusion of the
- the microdialysis probe is perfused with a 1 mM MnCl 2 solution in physiological saline at a flow rate of 10 ml / min for 30 minutes.
- the polysiloxane nanoparticles used consist of a polysiloxane matrix to which DOTAGA cyclic chelators are grafted. These nanoparticles have a hydrodynamic diameter of 1.5 ⁇ 6.3 nm. This size prevents their passage through the dialysis membrane, whose pore diameter is 2 to 3 nm.
- FIG. 1 The image obtained at the end of the perfusion of the MnCl 2 solution is presented in FIG. 1, and the image obtained at the end of the infusion with the suspension of nanoparticles is presented in FIG. 2.
- the microdialysis probe is perfused with a 1 mM MnCl 2 solution in physiological saline at a flow rate of 10 ml / min for 30 minutes.
- the microdialysis probe is then perfused with saline at 10 ml / min for 30 minutes.
- the image obtained at the end of the perfusion of the MnCl 2 solution is shown in FIG. 4, and the image obtained at the end of the infusion with the saline is presented in FIG. 5.
- FIG. corresponding to the difference of the two previous images and highlighting the absence of a drop in tissue concentration in Mn2 + (quasi-absence of highlighting at the level of the microdialysis probe).
- the animal is placed under gas anesthesia (2.5% isoflurane under 02 / N2 (80:20)) using a heating mat used during the procedure and the waking phase.
- gas anesthesia 2.5% isoflurane under 02 / N2 (80:20)
- lidocaine Xylovet 21.33 mg / ml
- lidocaine 4 mg / kg diluted in 0.9% NaCl with a volume injected 10 ⁇ l / g.
- the cranial box is disengaged in order to position a micro-drill (diameter ⁇ 1 mm) for the drilling of the cranial box.
- the probe is placed under stereotaxis.
- the dialysis cannula (diameter ⁇ 500 ⁇ m) is gently introduced into the brain at the desired position and depth. After positioning the cannula, a quick setting fixing resin is applied and screwed onto the skull of the animal. The skin is then sewn to close the wound. Before waking the animal, an analgesic (Buffycare) is administered subcutaneously. The administration of the analgesic is repeated at intervals of 8 to 12 hours for 2 days following the installation of the microdialysis probe. In order to limit the dehydration of the animal, a subcutaneous injection of 0.9% NaCl (of the order of 0.5 ml for the mouse, 5 ml for the rat) is carried out at the beginning of the procedure. To prevent dry eye, an ophthalmic ointment (Liposic) is applied at the beginning of the procedure.
- Liposic ophthalmic ointment
- the perfusion protocol for microdialysis is performed on D3.
- the protocol is carried out on animals under gas anesthesia (2.5% isoflurane under 02 / N2 (80:20)) using a heating mat used during the procedure and the waking phase and with control of the respiratory rate.
- the microdialysis probe (2 mm long, 6 kDa cutoff membrane, CM A Microdialysis AB, Kista, Sweden) is inserted into the microdialysis cannula and perfusion is performed at a flow rate of 10 m ⁇ / min.
- the perfusion is carried out for 30 minutes with a perfusate consisting of physiological saline supplemented with 1 mM of GdCl3 (solution 1).
- the dialysate is collected at the microdialysis outlet (solution 2).
- the dialysate is collected at the microdialysis outlet (solution 4).
- the nanoparticles used are identical to those of Example 1, that is to say that they have a hydrodynamic diameter of 1.5 ⁇ 6.3 nm. This size prevents their passage through the dialysis membrane, whose pore diameter is 2 to 3 nm.
- the chitosan used has an average molecular weight of 200 kDa.
- DTPA-BA Diethylenetriaminepentaacetic dianhydride
- VIVAFLOW cassettes were purchased from Sartorius and used as is.
- the infusion fluid was purchased from Phymep (Perfusion Fluid CNS Sterile, P000151) and used as is.
- a mass of 0.5 g of chitosan was weighed and inserted into a 500 ml container. A volume of 250 ml of distilled water was added and the solution was stirred. Using a pH meter and a 50% acetic acid solution, the pH was set at 4.0 ⁇ 0.1. The solution was stirred for 24 h. At 24 h the pH was again set at 4.0 ⁇ 0.1. This process was repeated until complete dissolution of all of the chitosan. A mass of 5.36 g of DTPA-BA was weighed and inserted into the resulting solution. The solution was stirred for 48 h.
- the solution was purified using a Vivaflow cassette with a cut-off of 100 kDa until a purification rate of at least 100,000 was achieved.
- a Vivaflow cassette the solvent is replaced by the CNS perfusion fluid of equal concentration.
- the chitosan used has an average molecular weight of 200 kDa.
- P-NCS-B 2 -DFO N 1 -hydroxy-N 1- (5- (4- (hydroxy (5- (3- (4-isothiocyanatophenyl) thioureido) pentyl) amino) -4-oxobutanamido) pentyl) N4- (5- (N-hydroxyacetamido) pentyl) succinamide was purchased from Chematech Mdt and used as is.
- VIVAFLOW cassettes were purchased from Sartorius and used as is.
- the infusion fluid was purchased from Phymep (Perfusion Fluid CNS Sterile, P000151) and used as is.
- a mass of 0.5 g of chitosan was weighed and inserted into a 500 ml container. A volume of 250 ml of distilled water was added and the solution was stirred. Using a pH meter and a 50% acetic acid solution, the pH was set at 4.0 ⁇ 0.1. The solution was stirred for 24 h. At 24 h the pH was again set at 4.0 ⁇ 0.1. This process was repeated until complete dissolution of all of the chitosan.
- a mass of 500 mg of p-NCS-Bz-DFO was weighed and inserted into the resulting solution.
- the solution was stirred for 48 h.
- the solution was purified using a Vivaflow cassette with a cut-off of 100 kDa until a purification rate of at least 100,000 was achieved.
- the solvent is replaced by the CNS perfusion fluid of equal concentration.
- VIVAFLOW cassettes were purchased from Sartorius and used as is.
- the infusion fluid was purchased from Phymep (Perfusion Fluid CNS Sterile, P000151) and used as is.
- a volume of 50 ml of 20% by weight Metalsorb was measured and inserted into a 250 ml container.
- a volume of 150 ml of water was added and the solution was put under stirring for 2 h.
- the solution was purified using a Vivaflow cassette with a 100 kDa cut-off threshold until a purification rate of at least 100,000 was reached.
- the The solvent is replaced by the CNS perfusion fluid of equal concentration.
- the materials obtained in Examples 3, 4 and 5 above can be used advantageously as means for extracting metal cations according to the present invention.
- the solutions can be used directly or by adapting the formulation to form an infusion fluid, or the polymers can be extracted and consolidated to form a macroscopic solid that can be implanted.
- the polysiloxane particles comprising EDTA (ethylenediaminetetraacetic) Si @ EDTA type chelates are obtained by mixing three silane precursors: (i) TEOS (Tertraethyl orthosilicate - ((Si (OC 2 H 5 ) 4 , 98% - Sigma-Aldrich Chemicals , France)), (ii) the APTES (3 (aminopropyl) triethoxy silane - (H 2 N (CH 2 ) 3 -Si (OC 2 H 5 ) 3, 99% - Sigma-Aldrich Chemicals, France)) and (iii ) Si-EDTA (N- (Trimethoxysilylpropyl) ethylenediaminetriacetic acid, trisodium salt - (N- [3-Trimethoxysilylpropyl] ethylenediamine triacetic acid trisodium salt 45% in water, ABCR, Germany).) The 3 precursors are placed in the DEG (d
- the mixture is stirred at room temperature for 30 minutes before adding a volume 3 times greater water and a new stirring phase of 17 hours at the same temperature.
- the temperature is then raised to 80 ° C and stirring is continued for 6 hours (the pH is adjusted to 7.4 after two hours of heating).
- the heating is then cut off and the solution is stirred for 17 hours.
- the solution is then purified by tangential filtration.
- the nanoparticles have a hydrodynamic diameter of 21 ⁇ 9 nm in Dynamic Light Scattering (DLS) evaluated using a Malvem Zeta Sizer Nano-S granulometer based on the PCS ( Figure 8).
- DLS Dynamic Light Scattering
- DTPA diethylenetriaminepentaaceticacid
- a preliminary step is necessary to graft the chelate onto a silane.
- the silane comprising DTPA is obtained by reacting a derivative of DTPA: DTPA-BA (diethylenetriaminepentaaceticacid dianhydride - CheMatech, Dijon, France) with the APTES in DEG with a ratio of 1 to 1 DTPA-BA / APTES. The solution is stirred for 24 hours. Then the TEOS is added with a ratio TEOS / APTES / DTPA-BA 3/1/1. After stirring for 1 hour in the DEG, water is added (10 times the volume of DEG used).
- the solution is then stirred for 24 hours at room temperature and then heated to 50 ° C and stirred again for 24 hours. Finally, the solution is cooled to room temperature and left stirring for 72 hours.
- the nanoparticles are then purified by tangential filtration and the pH is raised to 7.4.
- the nanoparticles have a hydrodynamic diameter of 7 ⁇ 3 nm in DLS, evaluated using a Malvem Zeta Sizer Nano-S granulometer based on PCS, with a second population at 20 ⁇ 7 nm ( Figure 9).
- the pH of the solution was adjusted to 7.4 and HEPES (4- (2-hydroxyethyl) -1-piperazine ethanesulfonic acid, Sigma-Aldrich Chemicals (France) was added as a buffer at a concentration of 1.2.
- the total volume of the solution is 600 ml
- the extraction by microdialysis lasted 40 min for flow rates of 2 and 5 ⁇ l / min
- the sample at 1 ⁇ l / min was obtained in 100 minutes, these samples were analyzed by ICP / MS and the amounts of each metal were reported in Table 2.
- Table 2 Concentration of the extracted metals in the perfusion fluid by comparing the water and polysiloxane nanoparticles - EDTA (15 mM) at different flow rates.
- Example 7 The relative effectiveness of the nanoparticles obtained in Examples 7 and 8 was compared using the same metal blend as described in Example 9 at a flow rate for the microdialysis 2 pL.min 1 and a sample collection time 40 min with a microdialysis membrane having a cut-off of 20 kDa.
- Table 3 summarizes the results obtained using 3 different infusion fluids: (i) water, (ii) polysiloxane-EDTA nanoparticles and (iii) polysiloxane-DTPA nanoparticles at a chelating agent concentration of 15 mM.
- DTPA-based nanoparticles have a very high aluminum extraction capacity because of the very high affinity of the agent chelating for this species. The presence of aluminum appears to saturate the surface chelating agents reducing the efficiency of the fluid for other metals.
- the polysiloxane - DTPA nanoparticles make it possible to obtain a very specific infusion fluid for the extraction of aluminum.
- Table 3 Concentration of the extracted metals in the perfusion fluid by comparing the water and polysiloxane-EDTA nanoparticles and polysiloxane-DTPA (15 mM) at a flow rate of 2 ⁇ L.min 1 .
- the microdialysis membrane (63 Microdialysis Catheter, M Dialysis AB, Sweden) used has a cut-off of 20 kDa and the flow rate was set at 2 ⁇ L ⁇ min-1 with a collection time of 40 min.
- the analysis of the quantities of metals extracted was carried out by ICP / MS.
- the perfusion fluid consisted of either reconstituted LCR or polysiloxane-EDTA nanoparticles whose synthesis is described in Example 7 dispersed in the reconstituted LCR.
- the results of the extraction are given in Table 4. It may be noted that the perfusion fluid containing only CSF has a very low extraction power.
- the addition of the nanoparticles in the perfusion fluid substantially increases the metal extraction whatever the metal. In these conditions, one thus gains a metal extraction factor of more than 5 for lead, more than 7 for copper, more than 25 for cadmium and more than 125 for aluminum.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- External Artificial Organs (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1763090A FR3075649A1 (fr) | 2017-12-22 | 2017-12-22 | Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations |
PCT/FR2018/053528 WO2019122790A1 (fr) | 2017-12-22 | 2018-12-21 | Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3727350A1 true EP3727350A1 (fr) | 2020-10-28 |
Family
ID=63294249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18842805.6A Pending EP3727350A1 (fr) | 2017-12-22 | 2018-12-21 | Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210205213A1 (fr) |
EP (1) | EP3727350A1 (fr) |
JP (2) | JP7446238B2 (fr) |
CN (2) | CN115845169A (fr) |
FR (1) | FR3075649A1 (fr) |
WO (1) | WO2019122790A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3109734A1 (fr) * | 2020-05-04 | 2021-11-05 | Mexbrain | Système de dialyse pour le traitement du sepsis |
FR3112960B1 (fr) * | 2020-07-29 | 2023-03-10 | Mexbrain | Dispositif de dialyse implantable pour l’extraction de molécules circulantes du liquide cérébrospinal et/ou du liquide interstitiel |
FR3112943A1 (fr) | 2020-07-29 | 2022-02-04 | Mexbrain | Polysaccharide comportant un groupement chélatant soluble à pH physiologique et utilisation de celui-ci ** |
FR3116197A1 (fr) * | 2020-11-19 | 2022-05-20 | Nh Theraguix | Procédé de traitement de tumeurs par captation du cuivre et/ou du fer |
FR3125705B1 (fr) * | 2021-07-30 | 2023-12-15 | Mexbrain | Composition pour la captation de plomb et/ou de cadmium dans un fluide de dialyse |
CN114539553B (zh) * | 2022-04-26 | 2022-09-06 | 深圳湾实验室 | 广谱抗氧化丝素蛋白及其制备方法和应用 |
WO2024008656A1 (fr) | 2022-07-04 | 2024-01-11 | Mexbrain | Utilisation médicale d'un chitosane fonctionnalisé |
WO2024038137A1 (fr) | 2022-08-18 | 2024-02-22 | Mexbrain | Utilisation médicale de polymère fonctionnalisé |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE510379A (fr) | 1951-04-04 | |||
JPS544490A (en) * | 1977-06-11 | 1979-01-13 | Toshimitsu Niwa | Device for removing copper ion contained in humor |
DE3270740D1 (en) * | 1981-06-29 | 1986-05-28 | Clara Ambrus | Apparatus for removing heavy metal ions from blood |
US5217998A (en) * | 1985-07-02 | 1993-06-08 | Biomedical Frontiers, Inc. | Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid |
DE4230513C1 (de) * | 1992-09-11 | 1994-03-31 | Fresenius Ag | Vorrichtung zur Entfernung von Aluminiumionen aus Blut und Lösung zur Verwendung in der Vorrichtung |
US6030358A (en) | 1997-08-08 | 2000-02-29 | Odland; Rick Matthew | Microcatheter and method for site specific therapy |
AU2004255216B2 (en) * | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
FR2959502B1 (fr) * | 2010-04-30 | 2012-09-07 | Nanoh | Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie |
FR2989280B1 (fr) * | 2012-04-13 | 2017-02-24 | Univ Claude Bernard Lyon | Nanoparticules ultrafines comme agent de contraste multimodal |
WO2014155144A1 (fr) * | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Llc | Nanocomposition stable comprenant du docétaxel, procédé pour sa préparation, son utilisation et compositions pharmaceutiques la contenant |
WO2014207490A1 (fr) * | 2013-06-28 | 2014-12-31 | Bbs Nanotechnology Ltd. | Agents de contraste de spect/mr(t1), spect/mr(t2) et spect/ct spécifiques d'une tumeur |
CN103977772B (zh) * | 2014-05-16 | 2016-01-13 | 大连理工大学 | 环糊精修饰磁性纳米吸附剂的制备方法及其在血液透析吸附系统中的应用 |
US11583621B2 (en) | 2015-05-27 | 2023-02-21 | Triomed Ab | Cartridge and apparatus for performing adsorption dialysis |
CN104984736A (zh) * | 2015-06-23 | 2015-10-21 | 中南大学 | 一种血液重金属吸附剂及其制备方法和血液灌流器 |
EP3192530A1 (fr) * | 2016-01-15 | 2017-07-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nanoparticules ultrafines comme agent d'imagerie pour el diagnostic d'une dysfonction rénale |
-
2017
- 2017-12-22 FR FR1763090A patent/FR3075649A1/fr active Pending
-
2018
- 2018-12-21 JP JP2020554946A patent/JP7446238B2/ja active Active
- 2018-12-21 CN CN202310045148.6A patent/CN115845169A/zh active Pending
- 2018-12-21 CN CN201880088861.6A patent/CN111936122A/zh active Pending
- 2018-12-21 EP EP18842805.6A patent/EP3727350A1/fr active Pending
- 2018-12-21 WO PCT/FR2018/053528 patent/WO2019122790A1/fr unknown
- 2018-12-21 US US16/955,923 patent/US20210205213A1/en active Pending
-
2023
- 2023-11-10 JP JP2023192504A patent/JP2024009057A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210205213A1 (en) | 2021-07-08 |
JP2021507801A (ja) | 2021-02-25 |
CN111936122A (zh) | 2020-11-13 |
FR3075649A1 (fr) | 2019-06-28 |
JP2024009057A (ja) | 2024-01-19 |
CN115845169A (zh) | 2023-03-28 |
JP7446238B2 (ja) | 2024-03-08 |
WO2019122790A1 (fr) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3727350A1 (fr) | Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations | |
CA2702919C (fr) | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants | |
Peng et al. | Carbon dots: promising biomaterials for bone-specific imaging and drug delivery | |
EP2563408B1 (fr) | Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale | |
Zhou et al. | Implications for blood-brain-barrier permeability, in vitro oxidative stress and neurotoxicity potential induced by mesoporous silica nanoparticles: Effects of surface modification | |
US20210221690A1 (en) | Nanoparticle compositions and methods of making and using the same | |
WO2022023677A1 (fr) | Polysaccharide comportant un groupement chélatant soluble à ph physiologique et utilisation de celui-ci | |
WO2019073182A1 (fr) | Nanovecteurs et utilisations | |
WO2020152426A1 (fr) | Dispositif d'extraction conjointe d'un cation métallique et d'une molécule cible | |
EP4376831A1 (fr) | Composition pour la captation de plomb et/ou de cadmium dans un fluide de dialyse | |
EP4247435A1 (fr) | Procédé de préparation de nanoparticules | |
EP4013511A1 (fr) | Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence | |
EP3192530A1 (fr) | Nanoparticules ultrafines comme agent d'imagerie pour el diagnostic d'une dysfonction rénale | |
EP4247428A1 (fr) | Procédé de traitement de tumeurs par captation du cuivre et/ou du fer | |
WO2022023679A1 (fr) | Dispositif de dialyse implantable pour l'extraction de molécules circulantes du liquide cérébrospinal et/ou du liquide interstitiel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200721 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LUX, FRANCOIS Inventor name: TILLEMENT, OLIVIER Inventor name: CREMILLIEUX, YANNICK Inventor name: BRICHART, THOMAS Inventor name: GROYER, SEBASTIEN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210416 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- Owner name: UNIVERSITE CLAUDE BERNARD - LYON 1 Owner name: MEXBRAIN |